Compare Lucid Group Inc (LCID) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs McKesson Corporation — how do they compare? Lucid Group Inc trades at $3.78 (market cap $1.51B), while McKesson Corporation trades at $937.1 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 71.8× Lucid Group Inc's market cap, and McKesson Corporation pays a 0.4% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and McKesson Corporation for 74 Days on average.
| LCID | MCK | |
|---|---|---|
Market Cap | $1.51B | $108.46B |
Volume | 12,333,745 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $995.69 |
52-Week Low | $3.82 | $725.17 |
Typical Hold Time | 45 Days | 74 Days |
Enterprise Value | $4.40B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.785, down 2.7% with a bearish technical outlook. The company shows concerning fundamentals with negative profit margins (-249.21% net income margin) and consistent earnings misses. Recent news highlights operational challenges including delayed Cosmos SUV launch and aggressive cost-cutting targets of $1.4 billion for 2026. Cash flow remains negative at -$566 million, though strategic partnerships with Bolt for autonomous vehicles provide some growth potential.
LCID faces significant execution risks amid high cash burn and competitive EV market pressures. Analyst consensus is cautious with 67% hold ratings and $7.60 price target suggesting 101% upside potential. The stock presents high-risk speculation for investors betting on successful turnaround execution and partnership developments.
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
